UZA Research Unit Oncology- route 55 PHASE 2
Welcome,         Profile    Billing    Logout  
 16 Trials 
24 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Prenen, Hans
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
SGNTUC-019, NCT04579380 / 2020-004873-29: Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Active, not recruiting
2
217
Europe, Japan, US, RoW
tucatinib, TUKYSA, ARRY-380, ONT-380, trastuzumab, Herceptin, fulvestrant, Faslodex
Seagen Inc., Seagen, Inc.
Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms, Carcinoma, Non-Small-Cell Lung, HER2 Mutations Breast Neoplasms
11/23
05/25
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
REGINA, NCT04503694 / 2020-000876-40: Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting
2
72
Europe
Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management
Jules Bordet Institute
Rectal Cancer Stage II, Rectal Cancer Stage III
01/26
12/30
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting
2
70
Europe
Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
09/25
12/26
BT5528-100, NCT04180371 / 2019-003653-29: Study in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Recruiting
1/2
288
Europe, US, RoW
BT5528, Nivolumab, Opdivo
BicycleTx Limited
Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
10/25
10/25
OPTIMIZE-1, NCT04888312 / 2020-005182-14: Safety and Efficacy of Mitazalimab in Combination with Chemotherapy in Pancreatic Cancer Patients

Active, not recruiting
1/2
94
Europe
CD40 agonist mitazalimab in combination with chemotherapy, ADC-1013, JNJ-64457107
Alligator Bioscience AB, Theradex, BC Platforms
Metastatic Pancreatic Ductal Adenocarcinoma
01/24
06/26
METex14, NCT04868877 / 2021-000203-20: Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Recruiting
1/2
576
Europe, US, RoW
MCLA-129, bispecific, Osimertinib, Tagrisso, Chemotherapy
Merus N.V.
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
03/26
03/27
NCT06667960: A Study of JK06 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Recruiting
1/2
155
Europe
JK06
Salubris Biotherapeutics Inc
Solid Tumor
04/28
08/28
NCT05159388: A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Active, not recruiting
1/2
45
Europe, US, RoW
PRS-344/S095012
Servier Bio-Innovation LLC, Institut de Recherches Internationales Servier
Solid Tumor
07/25
07/25
NCT05620134 / 2022-000339-21: Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Active, not recruiting
1/2
263
Europe
JK08, Pembrolizumab, Lenvatinib Pill
Salubris Biotherapeutics Inc, Salubris Biotherapeutics, Inc.
Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Melanoma, Colorectal Cancer, Non-small Cell Lung Cancer, Small-cell Lung Cancer, Urothelial Carcinoma, Squamous Cell Carcinoma of Head and Neck, Luminal Breast Cancer, Triple Negative Breast Cancer, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Gastric Adenocarcinoma, GastroEsophageal Cancer, Squamous Cell Carcinoma Skin, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Colorectal Adenocarcinoma, Epithelial Ovarian Cancer, Thyroid Cancer
10/25
02/26
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
Apr 2022 - Apr 2022: Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EMBER, NCT04188548 / 2019-003581-41: A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Active, not recruiting
1
500
Europe, Japan, US, RoW
LY3484356, Imlunestrant, Abemaciclib, LY2835219, Everolimus, Alpelisib, Trastuzumab, Aromatase Inhibitor (AI), Pertuzumab
Eli Lilly and Company
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
06/20
12/27
alloSHRINK, NCT03692429: - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

Checkmark From alloSHRINK trial for mCRC
Jul 2019 - Jul 2019: From alloSHRINK trial for mCRC
Hourglass Jul 2017 - Dec 2017 : Initiation of allogeneic P1 trial in cancer (unspecified tumor type)
: Topline data from alloSHRINK trial in colorectal
: Topline data from alloSHRINK trial in colorectal
More
Recruiting
1
49
Europe, US
CYAD-101, FOLFOX, FOLFIRI
Celyad Oncology SA
Unresectable Metastatic Colorectal Cancer
11/21
02/36
MCLA-145-CL01, NCT03922204: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

Completed
1
72
Europe, US
MCLA-145, bispecific, Pembrolizumab (Keytruda)
Merus N.V., Incyte Corporation
Advanced Cancer, Solid Tumor, Adult, B-cell Lymphoma, Adult
11/24
11/24
KEYNOTE-B79, NCT04991948: Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

Recruiting
1
34
Europe, US
CYAD-101, FOLFOX, Pembrolizumab
Celyad Oncology SA, Merck Sharp & Dohme Corp.
Unresectable Metastatic Colorectal Cancer
08/23
05/38
NCT04241835: A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Recruiting
1
24
Europe, US
Tazemetostat, EPZ-6438, IPN60200, Tazverik®
Epizyme, Inc., Sponsor GmbH
Hepatic Impairment, Advanced Malignant Solid Tumor
06/25
06/25
NCT05752552: Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients with Advanced or Refractory Solid Tumours

Recruiting
1
25
Europe
DO-2
DeuterOncology
Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor, Non-small Cell Lung Cancer, Non-small Cell Carcinoma, Lung Cancer, Hereditary Renal Papillary Cancer
12/25
12/26
CDR404-001, NCT06402201: First in Human Study of CDR404 in HLA-A*02:01 Participants with MAGE-A4 Expressing Solid Tumors

Recruiting
1
42
Europe, US
CDR404
CDR-Life AG
Select Advanced Solid Tumors
06/26
12/27
KISIMA-01, NCT04046445: Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Active, not recruiting
1
96
Europe, US
ATP128, BI 754091, Ezabenlimab, VSV-GP128
Amal Therapeutics, Boehringer Ingelheim
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
05/25
08/25
BALLETT, NCT05058937: A Study to Examine the Clinical Value of Comprehensive Genomic Profiling Performed by Belgian NGS Laboratories: a Belgian Precision Study of the BSMO in Collaboration With the Cancer Centre

Recruiting
N/A
936
Europe
Comprehensive genomic profiling
The Belgian Society of Medical Oncology, Illumina, Inc., OncoDNA, PierianDx
Solid Tumor, Metastatic Cancer
05/23
05/26
CAVACI, NCT05699915: Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors

Terminated
N/A
105
Europe
Cardiology consultation, Chest Computed Tomography (CT) without contrast, Cardiac CT, Non-invasive endothelial function tests, Flow mediated dilatation (FMD), Peripheral arterial tonometry (PAT), Electrocardiogram, ECG, Extra serum sample (7.5 mL)
Algemeen Ziekenhuis Maria Middelares
Cancer, Immune-related Adverse Event, Cardiac Abnormalities, Variable, Immune Checkpoint Inhibitor-Related Myocarditis, Diastolic Dysfunction, Atherosclerosis, Cardiotoxicity
07/24
07/24

Download Options